Average number of patients with medication orders per month, by intervention
| Preintervention | Postintervention | P value | |
| 1 January 2018–31 October 2020 | 1 November 2020–31 December 2021 | ||
| No of months | 34 | 14 | |
| Intervention medications | |||
| GLP-1 receptor agonists, mean (SD) | |||
| Dulaglutide | 26.0 (11.0) | 76.6 (18.4) | <0.001 |
| Liraglutide | 40.1 (7.7) | 63.1 (15.2) | <0.001 |
| Semaglutide | 10.8 (8.0) | 114.2 (66.4) | <0.001 |
| SGLT-2 Inhibitors, mean (SD) | |||
| Canagliflozin | 6.2 (2.5) | 10.9 (3.4) | <0.001 |
| Dapagliflozin | 5.8 (2.3) | 16.8 (8.2) | <0.001 |
| Empagliflozin | 38.0 (18.8) | 142.2 (40.5) | <0.001 |
| Control medications | |||
| Sulfonylureas, mean (SD) | |||
| Glimepiride | 92.9 (15.1) | 102.6 (13.0) | 0.041 |
| Glipizide | 57.6 (8.5) | 67.6 (10.8) | 0.002 |
| Glyburide | 6.9 (3.2) | 7.1 (2.6) | 0.89 |
| GLP-1 receptor agonists, mean (SD) | |||
| Exenatide | 11.4 (3.1) | 8.7 (2.5) | 0.006 |
GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose cotransporter-2.